Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

Lung cancer is the leading cause of cancer-related deaths worldwide. Next to adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic subtype in non-small cell lung cancer. Encouraging new treatments (i.e., bevacizumab, EGFR tyrosine kinase inhibitors, and ALK inhibi...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 18; no. 9; pp. 2443 - 2451
Main Authors PEREZ-MORENO, Pablo, BRAMBILLA, Elisabeth, THOMAS, Roman, SORIA, Jean-Charles
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.05.2012
Subjects
Adenocarcinoma - classification
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Antineoplastic agents
Biological and medical sciences
Carcinoma, Squamous Cell - classification
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - therapy
Dermatology
Humans
Lung Neoplasms - classification
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Medical sciences
Pharmacology. Drug treatments
Prognosis
Tumors of the skin and soft tissue. Premalignant lesions
Skin disease
Squamous cell carcinoma
Basal cell carcinoma
Treatment
Lung
Malignant tumor
Respiratory system
Cancer
Online AccessGet full text

Cover

More Information
Summary:Lung cancer is the leading cause of cancer-related deaths worldwide. Next to adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic subtype in non-small cell lung cancer. Encouraging new treatments (i.e., bevacizumab, EGFR tyrosine kinase inhibitors, and ALK inhibitors) have afforded benefits to patients with adenocarcinoma, but unfortunately the same is not true for SCC. However, many genomic abnormalities are present in SCC, and there is growing evidence of their biologic significance. Thus, in the short term, the molecular characterization of patients with SCC in modern profiling platforms will probably be as important as deciphering the molecular genetics of adenocarcinoma. Patients with SCC of the lung harboring specific molecular defects that are actionable (e.g., fibroblast growth factor receptor 1 amplification, discoidin domain receptor 2 mutation, and phosphoinositide 3-kinase amplification) should be enrolled in prospective clinical trials targeting such molecular defects.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.ccr-11-2370